Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain

• Published in: Translational psychiatry 2017-01, Vol.7 (1), p.e1003-e1003
• Main Authors: Purves-Tyson, T D, Owens, S J, Rothmond, D A, Halliday, G M, Double, K L, Stevens, J, McCrossin, T, Shannon Weickert, C
• Format: Article
• Language: English
• Subjects: 631/378/340; 692/699/476/1799; Adult; Aged; Antipsychotic Agents - therapeutic use; Autopsy; Behavioral Sciences; Biological Psychology; Blotting, Western; Case-Control Studies; Catechol O-Methyltransferase - genetics; Dopamine - metabolism; Dopamine Plasma Membrane Transport Proteins - genetics; Dopamine Plasma Membrane Transport Proteins - metabolism; Female; Humans; Male; Medicine; Medicine & Public Health; Mesencephalon - metabolism; Middle Aged; Monoamine Oxidase - genetics; Neostriatum - metabolism; Neurosciences; Original; original-article; Pharmacotherapy; Polymerase Chain Reaction; Presynaptic Terminals - metabolism; Psychiatry; Receptors, Dopamine D3 - genetics; RNA, Messenger - metabolism; Schizophrenia - drug therapy; Schizophrenia - genetics; Schizophrenia - metabolism; Tyrosine 3-Monooxygenase - metabolism; Vesicular Monoamine Transport Proteins - genetics; Young Adult
• ISSN: 2158-3188; 2158-3188
• DOI: 10.1038/tp.2016.257

The dopamine hypothesis of schizophrenia posits that increased subcortical dopamine underpins psychosis. In vivo imaging studies indicate an increased presynaptic dopamine synthesis capacity in striatal terminals and cell bodies in the midbrain in schizophrenia; however, measures of the dopamine-synthesising enzyme, tyrosine hydroxylase (TH), have not identified consistent changes. We hypothesise that dopamine dysregulation in schizophrenia could result from changes in expression of dopamine synthesis enzymes, receptors, transporters or catabolic enzymes. Gene expression of 12 dopamine-related molecules was examined in post-mortem midbrain (28 antipsychotic-treated schizophrenia cases/29 controls) using quantitative PCR. TH and the synaptic dopamine transporter (DAT) proteins were examined in post-mortem midbrain (26 antipsychotic-treated schizophrenia cases per 27 controls) using immunoblotting. TH and aromatic acid decarboxylase (AADC) mRNA and TH protein were unchanged in the midbrain in schizophrenia compared with controls. Dopamine receptor D2 short, vesicular monoamine transporter (VMAT2) and DAT mRNAs were significantly decreased in schizophrenia, with no change in DRD3 mRNA, DRD3nf mRNA and DAT protein between diagnostic groups. However, DAT protein was significantly increased in putatively treatment-resistant cases of schizophrenia compared to putatively treatment-responsive cases. Midbrain monoamine oxidase A (MAOA) mRNA was increased, whereas MAOB and catechol-O-methyl transferase mRNAs were unchanged in schizophrenia. We conclude that, whereas some mRNA changes are consistent with increased dopamine action (decreased DAT mRNA), others suggest reduced dopamine action (increased MAOA mRNA) in the midbrain in schizophrenia. Here, we identify a molecular signature of dopamine dysregulation in the midbrain in schizophrenia that mainly includes gene expression changes of molecules involved in dopamine synthesis and in regulating the time course of dopamine action.